Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.
The Australian group has found a partner for its lead asset at last, so why is the stock down?
A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.
Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.